The enduring potential of insulin: A legacy of life-changing innovation
MORE INFORMATION HERE 17:40 – 17:45 Symposium introduction Jay Skyler (USA) 17:45 – 18:00 100 years of insulin therapy for diabetes: From discovery to innovation
MORE INFORMATION HERE 17:40 – 17:45 Symposium introduction Jay Skyler (USA) 17:45 – 18:00 100 years of insulin therapy for diabetes: From discovery to innovation
17:40 – 17:55 Introduction:obesity, weight loss and CV risk Kim Connelly (CAN) 17:55 – 18:10 STEPping forward:cardiovascular risk factors in patients with overweight or obesity
09:15 – 09:20 Overview of oral semaglutide and PIONEER trials Filip K Knop (DNK) 09:20 – 09:30 Case scenarios based on clinical evidence Filip K
17:40 – 17:45 The case challengeTeaming up to tackle cardiorenal risk in diabetes Melanie Davies (UK) 17:45 – 17:55 Defining treatment goals: SGLT2i, implications from
17:40 – 17:45 Welcome Jordan Pinsker (USA) 17:45 – 18:00 One-Year Real-Life Use of Control-IQ Compared to Control-IQ Pivotal Trials Boris Kovatchev (USA) 18:00 –
19:30 – 19:35 Welcome and Introductions Carolina Piras de Oliveira (USA) 19:35 – 20:10 Review of Lyumjev (insulin lispro) multi-daily injection clinical studies in T1
09:35 – 09:45 Review the role of incretin hormones in physiology and type 2 diabetes pathophysiology Juan Pablo Frias (USA) 28.09.2021 09:35 – 09:45 Barcelona
17:40 – 17:45 Welcome James Mayjor (Ypsomed AG, AUS) 17:45 – 18:00 What is Android APS Neale Cohen (AUS) 18:00 – 18:10 Published data
17:40 – 17:50 The perspective of the patient with hypogonadism Geoff Hackett (UK) 17:50 – 18:05 Timely detection of hypogonadism: The importance of searching proactively
Chair: Pierre-Yves Benhamou (FRA) 19:30 – 19:35 Introduction Pierre-Yves Benhamou (FRA) 19:35 – 19:43 Germany: Experience from Germany with DBLG1 w Accu-Chek Insight: point of
